Drug intelligence / Profile preview

chlortetracycline

Development stage
Unknown
Lead developer
Pfizer
Modality
Small Molecules
Administration
Topical, Ophthalmic, Oral
01

Overview

Chlortetracycline is a broad-spectrum tetracycline antibiotic and was the first of its class to be discovered. It acts as a bacteriostatic agent by inhibiting bacterial protein synthesis. The drug binds to the 30S ribosomal subunit of bacteria, preventing aminoacyl-tRNA from attaching to the A site of the ribosome, thereby blocking peptide chain elongation and ultimately inhibiting bacterial growth and reproduction[1][6]. Chlortetracycline is primarily used in veterinary medicine for treating conjunctivitis in cats, dogs, and horses; infected wounds in cattle, sheep, and pigs; as well as respiratory tract infections in calves, pigs, and chickens[3]. In humans it is mainly used topically for eye infections or as part of combination creams for infected allergic dermatitis[2][3]. Its oral bioavailability is about 25-30% with peak plasma concentration reached within three hours after administration[1].

Brand names
Aureomycin
Other names
chlortetracycline hydrochloridechlortetracycline bisulfate
02

Targets

S3 (30S ribosomal protein S3)

Beyond the preview

Go deeper on chlortetracycline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on chlortetracycline.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call